药明康德
(603259)
| 流通市值：1683.62亿 | | | 总市值：1944.20亿 |
| 流通股本：25.01亿 | | | 总股本：28.88亿 |
| 报告期 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 39,241,431,359.88 | 27,702,002,254.76 | 17,240,918,263.02 | 7,981,934,236.96 |
| 营业收入 | 39,241,431,359.88 | 27,702,002,254.76 | 17,240,918,263.02 | 7,981,934,236.96 |
| 二、营业总成本 | 27,342,268,206.88 | 19,967,164,047.62 | 12,203,655,162.93 | 5,643,908,863.64 |
| 营业成本 | 22,964,515,460.62 | 16,440,256,129.17 | 10,453,936,890.44 | 4,938,382,494.26 |
| 税金及附加 | 301,181,005.49 | 218,784,249.97 | 146,876,170.27 | 68,532,047.64 |
| 销售费用 | 745,388,381.87 | 546,582,318.74 | 357,521,839.98 | 179,093,852.13 |
| 管理费用 | 2,879,341,988.34 | 1,869,468,114.84 | 1,212,235,637.14 | 575,859,743.18 |
| 研发费用 | 1,238,524,969.42 | 954,042,826.94 | 636,308,858.78 | 306,402,572.33 |
| 财务费用 | -786,683,598.86 | -61,969,592.04 | -603,224,233.68 | -424,361,845.9 |
| 其中:利息费用 | 216,033,816.34 | 150,222,876.33 | 107,053,052.78 | 51,078,664.38 |
| 其中:利息收入 | 626,757,006.25 | 467,311,764.91 | 316,477,649.99 | 161,136,417.95 |
| 加:公允价值变动收益 | 186,957,574.92 | 217,646,546.11 | -99,587,866.93 | -84,011,506.61 |
| 加:投资收益 | 604,162,381.66 | -164,809,637.05 | 22,379,410.5 | -8,925,102.88 |
| 资产处置收益 | -36,063,443.51 | -7,955,695.32 | -3,454,353.96 | -1,485,681.82 |
| 资产减值损失(新) | -1,236,257,969.76 | -20,104,426.49 | 11,412,652.34 | 6,594,693.15 |
| 信用减值损失(新) | -337,578,609.74 | -155,999,892.45 | -83,107,058.67 | -20,737,646.25 |
| 其他收益 | 499,791,631.57 | 287,254,161.42 | 193,548,192.9 | 80,387,049.85 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 11,580,174,718.14 | 7,890,869,263.36 | 5,078,454,076.27 | 2,309,847,178.76 |
| 加:营业外收入 | 22,254,764.5 | 5,586,936.32 | 4,035,872.06 | 1,664,315.57 |
| 减:营业外支出 | 62,617,843.56 | 42,160,110.47 | 32,936,177.98 | 14,117,354.53 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 11,539,811,639.08 | 7,854,296,089.21 | 5,049,553,770.35 | 2,297,394,139.8 |
| 减:所得税费用 | 1,972,072,099.9 | 1,252,684,573.24 | 768,708,087.44 | 338,540,934.85 |
| 六、净利润 | 9,567,739,539.18 | 6,601,611,515.97 | 4,280,845,682.91 | 1,958,853,204.95 |
| 持续经营净利润 | 11,396,829,426.64 | 6,601,611,515.97 | 4,280,845,682.91 | 1,958,853,204.95 |
| 终止经营净利润 | -1,829,089,887.46 | - | - | - |
| 归属于母公司股东的净利润 | 9,450,308,427.78 | 6,532,934,698.28 | 4,239,822,013.11 | 1,942,210,693.65 |
| 少数股东损益 | 117,431,111.4 | 68,676,817.69 | 41,023,669.8 | 16,642,511.3 |
| (一)基本每股收益 | 3.28 | 2.25 | 1.46 | 0.67 |
| (二)稀释每股收益 | 3.26 | 2.24 | 1.45 | 0.66 |
| 八、其他综合收益 | 185,718,884.52 | -3,353,834.76 | 14,733,694.61 | -213,721,368.52 |
| 归属于母公司股东的其他综合收益 | 188,583,091.93 | -3,156,713.02 | 17,103,453.09 | -210,365,488.48 |
| 九、综合收益总额 | 9,753,458,423.7 | 6,598,257,681.21 | 4,295,579,377.52 | 1,745,131,836.43 |
| 归属于母公司股东的综合收益总额 | 9,638,891,519.71 | 6,529,777,985.26 | 4,256,925,466.2 | 1,731,845,205.17 |
| 归属于少数股东的综合收益总额 | 114,566,903.99 | 68,479,695.95 | 38,653,911.32 | 13,286,631.26 |
| 公告日期 | 2025-03-18 | 2024-10-29 | 2024-07-30 | 2024-04-30 |
| 审计意见(境内) | 标准无保留意见 | | | |